Desferal - Deferoxamine

Venencie PY, Rain B, Blanc A, Tertian G. Toxidermie la deferoxamine (Desferal). [Deferoxamine (Desferal) dermatitis.] Ann Dermatol Venereol 1988 115(11) 1174. 

Deferoxamine (Desferal ) has a specific ability to chelate iron and is useful in treating acute iron intoxication. Deferoxamine can be administered... 

Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984 91(5) 443-51. 

Peck M, Rogers J, Riverbach J. Use of high doses of deferoxamine (Desferal) in an adult patient with acute iron overdosage. J Toxicol CUn Toxicol 1982 19 865-869. 

Deferoxamine deferoxamine mesylate, desferal mesylate) is poorly absorbed after oral administration, and parenteral administration is required in most cases. For severe iron toxicity (serum iron levels >500 /rg/dL), the intravenous route is preferred. The drug is administered at 10-15 mg/kg/h by constant infusion. Faster rates of infusion (45 mg/kg/h) have been used in a few cases rapid boluses usually are associated with hypotension. Deferoxamine may be given intramuscularly in moderately toxic cases (serum iron 350-500 )ig/dL) at a dose of 50 mg/kg with a maximum dose of 1 g. Hypotension also can occur with the intramuscular route. 

A. Parenteral. Deferoxamine mesylate (Desferal), vials containing 500 mg of lyophilized powder. 

---